JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.5 Billion JPY | 46.0% |
| 2022 | 3.77 Billion JPY | -74.0% |
| 2021 | 14.5 Billion JPY | 110.49% |
| 2020 | 6.89 Billion JPY | 157.36% |
| 2019 | 2.67 Billion JPY | -27.91% |
| 2018 | 3.71 Billion JPY | 21.01% |
| 2017 | 3.07 Billion JPY | 64.77% |
| 2016 | 1.86 Billion JPY | 4.12% |
| 2015 | 1.78 Billion JPY | 6.37% |
| 2014 | 1.68 Billion JPY | 29.79% |
| 2013 | 1.29 Billion JPY | 77.39% |
| 2012 | 730.71 Million JPY | 15.26% |
| 2011 | 633.98 Million JPY | -31.57% |
| 2010 | 926.47 Million JPY | -28.89% |
| 2009 | 1.3 Billion JPY | 141.31% |
| 2008 | 539.91 Million JPY | 34.99% |
| 2007 | 399.97 Million JPY | 122.84% |
| 2006 | -1.75 Billion JPY | -5395.42% |
| 2005 | -31.86 Million JPY | 97.5% |
| 2004 | -1.27 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -891 Million JPY | 126.27% |
| 2024 Q1 | 201 Million JPY | 689.22% |
| 2023 Q3 | -92 Million JPY | -102.53% |
| 2023 Q4 | 347 Million JPY | 477.17% |
| 2023 FY | 5.5 Billion JPY | 46.0% |
| 2023 Q1 | 1.61 Billion JPY | 689.22% |
| 2023 Q2 | 3.64 Billion JPY | 126.27% |
| 2022 Q4 | 204 Million JPY | -92.17% |
| 2022 FY | 3.77 Billion JPY | -74.0% |
| 2022 Q1 | 1.36 Billion JPY | -13.75% |
| 2022 Q2 | -406 Million JPY | -129.68% |
| 2022 Q3 | 2.6 Billion JPY | 741.87% |
| 2021 Q4 | 1.58 Billion JPY | -56.98% |
| 2021 Q3 | 3.68 Billion JPY | -52.13% |
| 2021 FY | 14.5 Billion JPY | 110.49% |
| 2021 Q1 | 1.53 Billion JPY | -57.77% |
| 2021 Q2 | 7.7 Billion JPY | 402.74% |
| 2020 Q3 | 2.03 Billion JPY | 342.83% |
| 2020 Q4 | 3.62 Billion JPY | 78.11% |
| 2020 FY | 6.89 Billion JPY | 157.36% |
| 2020 Q1 | 767 Million JPY | -12.14% |
| 2020 Q2 | 460 Million JPY | -40.03% |
| 2019 Q3 | 883 Million JPY | 59.67% |
| 2019 Q2 | 553 Million JPY | 49.86% |
| 2019 Q1 | 369 Million JPY | -80.03% |
| 2019 FY | 2.67 Billion JPY | -27.91% |
| 2019 Q4 | 873 Million JPY | -1.13% |
| 2018 FY | 3.71 Billion JPY | 21.01% |
| 2018 Q2 | 1.09 Billion JPY | 288.3% |
| 2018 Q3 | 490 Million JPY | -55.25% |
| 2018 Q4 | 1.84 Billion JPY | 277.14% |
| 2018 Q1 | 282 Million JPY | -51.96% |
| 2017 Q2 | 1.38 Billion JPY | 180.0% |
| 2017 FY | 3.07 Billion JPY | 64.77% |
| 2017 Q4 | 587 Million JPY | -2.49% |
| 2017 Q3 | 602 Million JPY | -56.57% |
| 2017 Q1 | 495 Million JPY | 10.8% |
| 2016 Q2 | 743 Million JPY | 166.31% |
| 2016 Q1 | 279 Million JPY | 10.8% |
| 2016 FY | 1.86 Billion JPY | 4.12% |
| 2016 Q4 | 446.73 Million JPY | 13.3% |
| 2016 Q3 | 394.29 Million JPY | -46.93% |
| 2015 Q1 | 448.95 Million JPY | -41.05% |
| 2015 Q4 | 251.8 Million JPY | -47.27% |
| 2015 FY | 1.78 Billion JPY | 6.37% |
| 2015 Q3 | 477.53 Million JPY | -21.87% |
| 2015 Q2 | 611.17 Million JPY | 36.13% |
| 2014 FY | 1.68 Billion JPY | 29.79% |
| 2014 Q2 | 192.79 Million JPY | -28.36% |
| 2014 Q3 | 458.9 Million JPY | 138.02% |
| 2014 Q4 | 761.54 Million JPY | 65.95% |
| 2014 Q1 | 269.12 Million JPY | 85.11% |
| 2013 Q3 | 712.11 Million JPY | 275.51% |
| 2013 Q4 | 145.39 Million JPY | -79.58% |
| 2013 Q2 | 189.64 Million JPY | -23.86% |
| 2013 Q1 | 249.06 Million JPY | -32.15% |
| 2013 FY | 1.29 Billion JPY | 77.39% |
| 2012 Q2 | 147.05 Million JPY | 133.21% |
| 2012 Q4 | 367.08 Million JPY | 139.11% |
| 2012 FY | 730.71 Million JPY | 15.26% |
| 2012 Q1 | 63.05 Million JPY | -39.35% |
| 2012 Q3 | 153.51 Million JPY | 4.39% |
| 2011 Q3 | 205.44 Million JPY | -0.94% |
| 2011 Q2 | 207.4 Million JPY | 77.01% |
| 2011 Q1 | 117.17 Million JPY | -15.32% |
| 2011 FY | 633.98 Million JPY | -31.57% |
| 2011 Q4 | 103.96 Million JPY | -49.4% |
| 2010 Q1 | 551.24 Million JPY | 809.77% |
| 2010 Q4 | 138.37 Million JPY | -24.12% |
| 2010 FY | 926.47 Million JPY | -28.89% |
| 2010 Q3 | 182.36 Million JPY | 234.73% |
| 2010 Q2 | 54.48 Million JPY | -90.12% |
| 2009 Q3 | 1.12 Billion JPY | 916.11% |
| 2009 Q4 | 60.59 Million JPY | -94.62% |
| 2009 FY | 1.3 Billion JPY | 141.31% |
| 2009 Q2 | -138.11 Million JPY | -154.55% |
| 2009 Q1 | 253.2 Million JPY | -20.42% |
| 2008 Q4 | 318.18 Million JPY | -43.62% |
| 2008 FY | 539.91 Million JPY | 34.99% |
| 2008 Q3 | 564.4 Million JPY | 466.36% |
| 2008 Q2 | -154.05 Million JPY | 0.0% |
| 2007 FY | 399.97 Million JPY | 122.84% |
| 2006 FY | -1.75 Billion JPY | -5395.42% |
| 2005 FY | -31.86 Million JPY | 97.5% |
| 2004 FY | -1.27 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 81.18 Billion JPY | 93.217% |
| Astellas Pharma Inc. | 17.04 Billion JPY | 67.691% |
| Chugai Pharmaceutical Co., Ltd. | 325.47 Billion JPY | 98.308% |
| Ono Pharmaceutical Co., Ltd. | 127.97 Billion JPY | 95.697% |
| Santen Pharmaceutical Co., Ltd. | 26.64 Billion JPY | 79.33% |
| Daiichi Sankyo Company, Limited | 200.73 Billion JPY | 97.257% |
| Otsuka Holdings Co., Ltd. | 121.61 Billion JPY | 95.472% |
| Perseus Proteomics Inc. | -1.1 Billion JPY | 598.615% |